Tyler Van Buren
Stock Analyst at TD Cowen
(2.47)
# 2,410
Out of 5,115 analysts
59
Total ratings
45.83%
Success rate
2.71%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CCCC C4 Therapeutics | Initiates: Buy | n/a | $1.90 | - | 1 | Dec 2, 2025 | |
| BHVN Biohaven | Maintains: Buy | $50 → $15 | $11.83 | +26.80% | 3 | Nov 5, 2025 | |
| MBX MBX Biosciences | Initiates: Buy | n/a | $36.85 | - | 1 | Nov 4, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $30 → $40 | $31.09 | +28.66% | 2 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $60 → $95 | $77.27 | +22.95% | 2 | Oct 30, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $115 → $125 | $141.95 | -11.94% | 6 | Oct 23, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | n/a | $32.19 | - | 1 | Jul 22, 2025 | |
| CGON CG Oncology | Initiates: Buy | n/a | $52.05 | - | 1 | Jan 7, 2025 | |
| KROS Keros Therapeutics | Downgrades: Hold | n/a | $17.92 | - | 2 | Dec 12, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | n/a | $16.80 | - | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $34.23 | - | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $70 → $60 | $44.07 | +36.15% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $3.89 | - | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $6.83 | - | 1 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,030 → $1,200 | $741.45 | +61.85% | 7 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $19.99 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $31.12 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $49.96 | -39.95% | 2 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $31.98 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $68.31 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $65.51 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.19 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $32.55 | +115.05% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.43 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.38 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $30.82 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $225 | $9.59 | +2,246.19% | 1 | Feb 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $8.07 | +10,742.63% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $16.52 | +142.13% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $18.94 | +58.39% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.21 | +4,032.23% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $2.28 | +1,215.79% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.69 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $34.08 | - | 1 | Aug 4, 2017 |
C4 Therapeutics
Dec 2, 2025
Initiates: Buy
Price Target: n/a
Current: $1.90
Upside: -
Biohaven
Nov 5, 2025
Maintains: Buy
Price Target: $50 → $15
Current: $11.83
Upside: +26.80%
MBX Biosciences
Nov 4, 2025
Initiates: Buy
Price Target: n/a
Current: $36.85
Upside: -
Travere Therapeutics
Oct 31, 2025
Maintains: Buy
Price Target: $30 → $40
Current: $31.09
Upside: +28.66%
BridgeBio Pharma
Oct 30, 2025
Maintains: Buy
Price Target: $60 → $95
Current: $77.27
Upside: +22.95%
Gilead Sciences
Oct 23, 2025
Maintains: Buy
Price Target: $115 → $125
Current: $141.95
Upside: -11.94%
IDEAYA Biosciences
Jul 22, 2025
Initiates: Buy
Price Target: n/a
Current: $32.19
Upside: -
CG Oncology
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $52.05
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $17.92
Upside: -
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $16.80
Upside: -
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $34.23
Upside: -
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $44.07
Upside: +36.15%
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $3.89
Upside: -
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $6.83
Upside: -
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $741.45
Upside: +61.85%
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $19.99
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $31.12
Upside: -
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $49.96
Upside: -39.95%
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $31.98
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $68.31
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $65.51
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.19
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $32.55
Upside: +115.05%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $2.43
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $13.38
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $30.82
Upside: -
Feb 10, 2021
Initiates: Overweight
Price Target: $225
Current: $9.59
Upside: +2,246.19%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $8.07
Upside: +10,742.63%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $16.52
Upside: +142.13%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $18.94
Upside: +58.39%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.21
Upside: +4,032.23%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $2.28
Upside: +1,215.79%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $11.69
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $34.08
Upside: -